Debiopharm Research & Manufacturing

Founded in 1981 in Martigny by Dr Rolland-Yves Mauvernay under the name of Cytotech, Debiopharm Research & Manufacturing is a pioneering manufacturer of injectable products based on polylactic-co-glycolic acid (PLGA) for controlled release. These products are used in the treatment of advanced prostate cancer and certain hormone-related problems in women (endometriosis and in vitro fertilisation) and children (precocious puberty). Controlled release has enabled patients to move from daily injections to monthly, three-monthly and, more recently, six-monthly injections.

Every year, more than 300,000 people throughout the world are treated with Debiopharm products developed or manufactured in Martigny, with proven efficacy and safety. Debiopharm Research & Manufacturing is also actively involved in pharmaceutical research and development. At the company’s Valais laboratory, 45 researchers study and investigate peptides – small proteins – as well as target peptides in oncology and the treatment of infection.

In Martigny, Debiopharm employs a workforce of more than 140 from 15 different countries, of whom 40% are scientists and engineers. The company is directed by Cédric Sager.

Debiopharm Research & Manufacturing SA is a pharmaceutical research, development and production company equipped with installations that comply with the GMP (Good Manufacturing Practice) standards and are certified by the regulatory authorities. A centre of expertise for the group in the field of therapeutic chemistry, the company is a key player in the field of injectable products based on polylactic-co-glycolic acid (PLGA).

Debiopharm Group
Based in Lausanne, the Debiopharm Group™ is an international biopharmaceutical group made up of four companies – Debiopharm International, Debiopharm Research & Manufacturing, Debiopharm Diagnostics and Debiopharm Investment – which operate in the fields of drug development, the manufacture of exclusive medicines, diagnostics and investments. The group acquires licences then develops and/or co-develops molecules and promising biological products with a view to global registration. The products are marketed by means of licences granted to pharmaceutical partners in order to make them accessible to as many patients as possible all over the world.